NCT02085070 - Pembrolizumab (IV) & Brain metastasis (In: Melanoma (cutaneous), Non-small-cell lung carcinoma (NSCLC))

Allocation: Non-Randomized, Interventional Model: Single Group Assignment, Masking: None (Open Label)
Primary Outcome measures:
Overall Response in the Brain

Pembrolizumab is active in melanoma brain metastases with acceptable toxicity and durable responses. Multidisciplinary care is required to optimally manage patients with brain metastases, including consideration of radiation to large or symptomatic lesions, which were excluded in this trial. Two-year survival was similar to patients without brain metastasis treated with anti–programmed cell death 1 agents. Concordant brain and extracerebral responses support use of pembrolizumab to treat small, asymptomatic brain metastases
Kluger et al. 2019 JCO 37: 52–60
…